Medhealth Review

Sage Therapeutics To Outline 2025 Strategy At J.P. Morgan Healthcare Conference

Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that its CEO, Barry Greene, will present the company’s strategic focus for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Greene will highlight the commercialization and growth plans for ZURZUVAE® (zuranolone), the first and only 14-day oral treatment for postpartum depression (PPD). He will also discuss the company’s recalibrated R&D approach and its emphasis on neurodevelopmental disorders and neuropsychiatry, with a reduction in R&D and G&A expenses expected in 2025.

ZURZUVAE has shown significant potential in its first year, positioning itself as the potential standard of care for PPD, an area with limited treatment options. Sage’s commercial strategy includes expanding the sales force, launching digital marketing campaigns, and increasing awareness to improve PPD screening and diagnosis. These efforts aim to accelerate market growth and increase topline revenue in 2025.

SAGE-319, a novel GABAA receptor positive allosteric modulator, is currently under investigation for treating behavioral symptoms in neurodevelopmental disorders. Sage expects data from its Phase 1 multiple ascending dose study by late 2025 and will decide next steps based on the results.

Additionally, Sage is evaluating SAGE-324 for potential use in treating seizures related to developmental and epileptic encephalopathies (DEEs), with updates expected in mid-2025. The company is also progressing with early discovery work in its NMDA NAMs platform.

Financially, Sage anticipates its cash, equivalents, and marketable securities, along with funding from collaborations and projected revenues, will support operations through mid-2027. While commercialization expenses for ZURZUVAE with Biogen will increase, the company expects a significant reduction in overall operating costs in 2025, thanks to a focused pipeline and cost-saving measures from a 2024 reorganization.

Must Read
Related Articles